Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded by Bank of America to “Neutral”

Bank of America upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from an underperform rating to a neutral rating in a report issued on Friday morning, Marketbeat reports.

Separately, The Goldman Sachs Group began coverage on shares of Bayer Aktiengesellschaft in a report on Thursday, May 30th. They issued a neutral rating on the stock. One equities research analyst has rated the stock with a sell rating and nine have issued a hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Hold.

Bayer Aktiengesellschaft Price Performance

OTCMKTS:BAYRY opened at $8.01 on Friday. The stock’s 50-day simple moving average is $7.40 and its 200 day simple moving average is $7.43. Bayer Aktiengesellschaft has a 52-week low of $6.82 and a 52-week high of $13.82. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.27. The company has a market cap of $31.48 billion, a P/E ratio of -9.21 and a beta of 1.04.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.25 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.25. The company had revenue of $12 billion for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. As a group, sell-side analysts forecast that Bayer Aktiengesellschaft will post 1.37 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.